Literature DB >> 8187809

Human leucocyte-endothelial interactions in peripheral arterial occlusive disease.

G Ciuffetti1, R Lombardini, R Paltriccia, L Santambrogio, E Mannarino.   

Abstract

This ex vivo study determined the expression of leucocyte adhesion receptors for endothelial adhesion molecules in 10 patients with peripheral arterial occlusive disease (PAOD) and in 10 healthy controls before and after treadmill exercise. Granulocytes from venous blood samples were separated on a Ficoll-Hypaque gradient and the phenotypical expression of CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1) and CD11c/CD18 (p150,95) was observed by double indirect immunofluorescence using specific monoclonal antibodies. The total and differential white blood cell counts were monitored before and after exercise. In the PAOD patients a significant reduction in the number of granulocytes expressing CD11b/CD18 (Mac-1) and CD11c/CD18 (p150,95) associated with a significant neutropenia was observed after exercise, suggesting that leucocyte-endothelial interactions occur during ischaemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187809     DOI: 10.1111/j.1365-2362.1994.tb02061.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

Review 1.  Adhesion molecules, catecholamines and leucocyte redistribution during and following exercise.

Authors:  Roy J Shephard
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

2.  Increased surface expression of CD18 and CD11b in leukocytes after tourniquet ischemia during elective hand surgery.

Authors:  P M Sutter; G C Spagnoli; A Marx; L Gürke; H Troeger; R Fricker; F Harder; M Heberer
Journal:  World J Surg       Date:  1997-02       Impact factor: 3.352

3.  Attenuation of changes in capillary fine structure and leukocyte adhesion improves muscle performance following chronic ischaemia in rats.

Authors:  O Hudlická; A Garnham; R Shiner; S Egginton
Journal:  J Physiol       Date:  2008-08-28       Impact factor: 5.182

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.